We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

CEPHEID

Develops, manufactures, and markets molecular systems and tests for institutions to perform sophisticated genetic tes... read more Featured Products: More products

Download Mobile App




Rapid Norovirus Assay Approved for Diagnostic Use in the United States

By LabMedica International staff writers
Posted on 15 Dec 2014
A dedicated laboratory-in-a-cartridge assay that enables the rapid diagnosis of norovirus infection has been approved for use in the United States.

The Food and Drug Administration (FDA) approved the single use Xpert Norovirus assay, which runs on Cepheid's (Sunnyvale, CA, USA) GeneXpert System, one of the world's leading molecular diagnostic platforms with more than 7,000 systems installed to date. More...
The Xpert Norovirus assay is a qualitative in vitro diagnostic test for rapid identification and differentiation of noroviruses genogroup I (GI) and genogroup II (GII).

Cepheid's GeneXpert System is a closed, self-contained, fully-integrated, and automated platform that combines on-board sample preparation with real-time PCR (polymerase chain reaction) amplification and detection functions for fully integrated and automated nucleic acid analysis. The system is designed to purify, concentrate, detect, and identify targeted nucleic acid sequences thereby delivering answers directly from unprocessed samples.

"Norovirus exposure is an unfortunate fact of life. The associated illness can spread quickly in the hospital setting and be very serious, especially in young children and older adults," said John Bishop, CEO of Cepheid. "To actively manage the infection, clinicians have previously been forced to choose between accuracy and time-to-result when selecting a testing method — now no compromise is required as Xpert Norovirus delivers both."

"Xpert Norovirus enables on-demand molecular detection and differentiation of the GI and GII Norovirus genogroups, which together account for the vast majority of human infections," said Dr. David H. Persing, CMO and CTO at Cepheid. "Norovirus outbreaks require immediate implementation of targeted infection control procedures, and this new test gives clinicians accurate results in as little as one hour."

Related Links:

Cepheid




Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Aspiration System
VACUSAFE
Automated Urinalysis Solution
UN-9000
Automatic CLIA Analyzer
Shine i6000
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Researchers developed three mathematical biomarkers from routine PSA blood tests that may help predict early prostate cancer treatment outcomes and personalize adaptive therapy (Image Credit: Adobe Stock)

Mathematical Biomarkers Use Routine Blood Tests to Guide Adaptive Prostate Cancer Therapy

Personalizing systemic therapy for prostate cancer remains challenging because tumors can evolve under treatment pressure, driving resistance and early relapse. Continuous high-dose regimens may initially... Read more

Molecular Diagnostics

view channel
Image: The duet mosaic family comprises duet +modC mosaic and duet 6-base mosaic, two cfDNA-optimized multiomic sequencing workflows for liquid biopsy and translational research. (Photo courtesy of bimodal)

New Liquid Biopsy Workflow Maximizes Tumor Signals from Limited Blood Samples

Liquid biopsy seeks to detect tumor-derived signals from small blood samples, but circulating cell-free DNA is scarce and heterogeneous, limiting sensitivity. Combining complementary signals such as methylation,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.